Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for NAFLD without Diabetes
NCT04642261Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Empagliflozin group with Placebo group (2 arms). Primary endpoint: Change in liver fat content measured by MRI-PDFF at 52 weeks. Started Jan 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04642261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642261.